Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

Fig. 2

Erlotinib, nelfinavir or nitroxoline affect cell cycle in AsPC-1, Capan-2 and BxPC-3. The histograms show the mean percentage of cells in the different cell cycle phases after 72 h of treatment with vehicle, or with low concentrations (a, c and e, left), or high concentrations (b, d and f, left) of nitroxoline, nelfinavir and erlotinib as single agents. Data are the means ± SD of two independent flow cytometry experiments. The expression of cyclin D3 and cyclin B1 proteins after 48 h of treatment with the three drugs at the indicated concentrations was analyzed by western blot (A-F, right). *Statistically significant differences as compared to the corresponding value of vehicle (*p < 0.05; **p < 0.01; ***p < 0.001). The mean percentages of hypodiploid cells (identified as apoptotic sub-G1 population) following treatments are shown in Additional file 2: Table S2

Back to article page